Welcome to International Network for Natural Sciences | INNSpub

Role of extrapolative factors in the development of Hyperprolactinemia Mediated Depression (HMD) in schizophrenics susceptible to thyroid disorders

Research Paper | November 1, 2016

| Download 3

Arif Malik, Shamaila Saleem, Muhammad Abdul Basit Ashraf, Muhammad Asif, Sulayman Waquar, Mahmood Husain Qazi, Qasir Abbas, Asim Iqbal, Kashif Kamran, Mohammad Zahid Mustafa, Ahmad Zaheer, Muhammad Arshad, Amir Raza, Sabra Akbar, Mahmood Rasool

Key Words:

Int. J. Biosci.9( 5), 183-189, November 2016

DOI: http://dx.doi.org/10.12692/ijb/9.5.183-189


IJB 2016 [Generate Certificate]


A cross sectional prospective study was designed to find out the prophetic effect of hyperprolactinemia mediated depression (HMD) in schizophrenics susceptible to thyroid disorders. One hundred newly diagnosed patients (61 males and 29 females) suffering from schizophrenia in the age group of 24-67 years were recruited in the study. Fifty age and sex matched, healthy individuals (25 males and 25 females) were included as controls (23-63 Years). Important biomarkers like T3 (Triiodothyronine), T4 (Thyroxine), TSH (Thyroid stimulating hormone), tumor necrosis factor alpha (TNF-α), Dopamine, Prolactin, Estradiol, Serotonin, Zn and Cu were estimated and compared in schizophrenics and controls. Higher levels of FT4, TSH, TNF-α, Zn, prolactin and serotonin were recorded (25.12±3.05 pmol/L, 4.48±.18 IU/L, 34.75±2.09pg/ml, 0.30±0.0019mg/L, 30.60±2.08ng/ml and 175.85±7.06ng/ml respectively) in schizophrenia patients as compared to healthy controls. While lower levels of FT3, Cu, dopamine and estradiol were measured (3.94±0.35μg/dl, 1.03±0.056mg/L, 3.87±0.668pg/ml and 6.75±0.97pg/ml respectively) in schizophrenia patients as compared to healthy controls. The present study depicts that hypoestrogenism and disturbed prolactin-serotonin-dopamine interactions are the major role players in the pathogenesis of schizophrenia. Hypoestrogenism and reduced copper levels affect dopamine levels negatively while high levels of zinc induce serotonin production, both of these effects result in hyperprolactinemia mediated depression (HMD) and susceptibility to hyperthyroidism. Thus, by regulating these factors not only schizophrenic symptoms but also progression to thyroid disorders can be controlled.


Copyright © 2016
By Authors and International Network for
Natural Sciences (INNSPUB)
This article is published under the terms of the Creative
Commons Attribution Liscense 4.0

Role of extrapolative factors in the development of Hyperprolactinemia Mediated Depression (HMD) in schizophrenics susceptible to thyroid disorders

Asare GA, Tetteh R, Amedonu E, Asiedu B, Doku D. 2014. Toxicity, Deficiency and Dysmetabolism of Trace Elements in Ghanaian Clinically Stable Schizophrenics. Macedonian Journal of Medical Sciences 7(2), 295-300.

Azcoitia I, Arevalo MA, De Nicola AF, Garcia-Segura LM. 2011. Neuroprotective actions of estradiol revisited. Trends in Endocrinology & Metabolism 22(12), 467-473.

Bethea CL, Lu NZ, Gundlah C, Streicher JM. 2002. Diverse actions of ovarian steroids in the serotonin neural system. Frontiers in neuroendocrinology 23(1), 41-100.

Bitanihirwe BK, Woo T-UW. 2011. Oxidative stress in schizophrenia: an integrated approach. Neuroscience & Biobehavioral Reviews 35(3), 878-893.

Blankenstein T, Qin Z, Uberla K, Müller W, Rosen H, Volk HD, Diamantstein T. 1991. Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. The Journal of experimental medicine 173(5), 1047-1052.

Cai L, Chen T, Yang J, Zhou K, Yan X, Chen W, Sun L, Li L, Qin S, Wang P. 2015. Serum trace element differences between Schizophrenia patients and controls in the Han Chinese population. Scientific reports 5.

Ciobica A, Padurariu M, Dobrin I, Stefanescu C, Dobrin R. 2011. Oxidative stress in schizophrenia-focusing on the main markers. Psychiatria Danubina 23(3), 237-245.

Dejong H, Van den Eynde F, Broadbent H, Kenyon M, Lavender A, Startup H, Schmidt U. 2013. Social cognition in bulimia nervosa: a systematic review. European Psychiatry 28(1), 1-6.

Gillies GE, McArthur S. 2010. Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines. Pharmacological reviews 62(2), 155-198.

González-Blanco L, Greenhalgh AMD, Garcia-Rizo C, Fernandez-Egea E, Miller BJ, Kirkpatrick B. 2016. Prolactin concentrations in antipsychotic-naïve patients with schizophrenia and related disorders: A meta-analysis. Schizophrenia Research.

Gragnoli C, Reeves G, Reazer J, Postolache T. 2016. Dopamine–prolactin pathway potentially contributes to the schizophrenia and type 2 diabetes comorbidity. Translational psychiatry 6(4), e785.

Gupta P, Kar A. 1999. Cadmium induced thyroid dysfunction in chicken: hepatic type I iodothyronine 5′-monodeiodinase activity and role of lipid peroxidation. Comparative Biochemistry and Physiology Part C: Pharmacology, Toxicology and Endocrinology 123(1), 39-44.

Halbreich U, Kinon B, Gilmore J, Kahn L. 2003. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 28, 53-67.

Johnson S. 2001. Micronutrient accumulation and depletion in schizophrenia, epilepsy, autism and Parkinson’s disease? Medical hypotheses 56(5), 641-645.

Kaur SS, Gonzales MM, Eagan DE, Goudarzi K, Tanaka H, Haley AP. 2015. Inflammation as a mediator of the relationship between cortical thickness and metabolic syndrome. Brain imaging and behavior 9(4), 737-743.

Kema IP, de Vries EG, Muskiet FA. 2000. Clinical chemistry of serotonin and metabolites. Journal of Chromatography B: Biomedical Sciences and Applications 747(1), 33-48.

Kim J, Jeon M, Paeng K-J, Paeng IR. 2008. Competitive enzyme-linked immunosorbent assay for the determination of catecholamine, dopamine in serum. analytica chimica acta 619(1), 87-93.

Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. 2010. The schizophrenia patient outcomes research team (PORT): updated treatment recommendations 2009. Schizophrenia bulletin 36(1), 94-103.

Kurz D, Roach J, Eyring EJ. 1972. Direct determination of serum zinc and copper by atomic absorption spectrophotometry. Biochemical medicine 6(3), 274-281.

Leucht S, Burkard T, Henderson J, Maj M, Sartorius N. 2007. Physical illness and schizophrenia: a review of the literature. Acta Psychiatrica Scandinavica 116(5), 317-333.

Liu T, Lu Q-B, Yan L, Guo J, Feng F, Qiu J, Wang J. 2015. Comparative Study on Serum Levels of 10 Trace Elements in Schizophrenia. PLoS One 10(7), e0133622.

MacDonald AW, Schulz SC. 2009. What we know: findings that every theory of schizophrenia should explain. Schizophrenia bulletin 35(3), 493-508.

Malashenkova I, Krynskiy S, Khailov N, Kazanova G, Velichkovsky B, Didkovsky N. 2016. The role of cytokines in memory consolidation. Biology Bulletin Reviews 6(2), 126-140.

Naber D, Finkbeiner C, Fischer B, Zander KJ, Ackenheil M. 1980. Effect of long-term neuroleptic treatment on prolactin and norepinephrine levels in serum of chronic schizophrenics: relations to psychopathology and extrapyramidal symptoms. Neuropsychobiology 6(4), 181-189.

Pataracchia RJ. 2005. Optimal Dosing for Schizophrenia. Journal of Orthomolecular Medicine 20(2).

Peterson BM, Mermelstein PG, Meisel RL. 2015. Estradiol mediates dendritic spine plasticity in the nucleus accumbens core through activation of mGluR5. Brain Structure and Function 220(4), 2415-2422.

Prabakaran S, Swatton J, Ryan M, Huffaker S, Huang JJ, Griffin J, Wayland M, Freeman T, Dudbridge F, Lilley K. 2004. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Molecular psychiatry 9(7), 684-697.

Santos NC, Costa P, Ruano D, Macedo A, Soares MJ, Valente J, Pereira AT, Azevedo MH, Palha JA. 2012. Revisiting thyroid hormones in schizophrenia. Journal of thyroid research 2012.

Supit EJ, Peiris AN. 2002. Interpretation of laboratory thyroid function tests for the primary care physician.(Featured CME Topic: Thyroid Dysfunction/Disease). Southern medical journal 95(5), 481-486.

Vidović B, Đorđević B, Milovanović S, Škrivanj S, Pavlović Z, Stefanović A, Kotur-Stevuljević J. 2013. Selenium, zinc, and copper plasma levels in patients with schizophrenia: relationship with metabolic risk factors. Biological trace element research 156(1-3), 22-28.

Weickert TW, Allen KM, Weickert CS. 2016. Potential Role of Oestrogen Modulation in the Treatment of Neurocognitive Deficits in Schizophrenia. CNS drugs 30(2), 125-133.

Wysokiński A, Kłoszewska I. 2014. Level of thyroid-stimulating hormone (TSH) in patients with acute schizophrenia, unipolar depression or bipolar disorder. Neurochemical research 39(7), 1245-1253.

Yanik M, Vural H, Tutkun H, Zoroğlu SS, Savaş HA, Herken H, Koçyiğit A, Keleş H, Akyol Ö. 2004. The role of the arginine-nitric oxide pathway in the pathogenesis of bipolar affective disorder. European archives of psychiatry and clinical neuroscience 254(1), 43-47.